Familial Hypercholesterolemia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Familial Hypercholesterolemia is a moderately active landscape with 37 programs across 20 companies. The most active players are Verve Therapeutics, Inc., Ionis Pharmaceuticals, Esperion Therapeutics, Inc.. 1 therapy is approved with 19 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Verve Therapeutics, Inc.
2 programs
Ionis Pharmaceuticals
1 program
Esperion Therapeutics, Inc.
1 program
Madrigal Pharmaceuticals
1 program
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2 programs
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
83%
Small molecule
33 of 40 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.
Analysis
Trial Status
52
clinical trials
Clinical Trials
Trial Activity
52 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)